Skip to main content

Table 1 Ligands and inhibitors of protein tyrosine kinases

From: Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma

Protein tyrosine kinase Ligand Monoclonal antibody of ligand Representative TKI
VEGFR VEGF (A, -B, -C, -D, -E) Bevacizumab, aflibercept, ramucirumab (anti-VEGFR2) Sorafenib, sunitinib, axitinib, pazopanib
EGFR EGF, TGFα, HB-EGF, amphiregulin, epiregulin, epigen, β-cellulin, NRG 2 β Nimotuzumab, panitumumab, cetuximab, necitumumab (anti-EGFR) Erlotinib, afatinib, osimertinib, sapitinib
PDGFR PDGF Olaratumab (anti-PDGFRα) Imatinib, pazopanib
c-MET (HGFR) HGF   Cabozantinib [19], crizotinib
HER2   Trastuzumab,ramucirumab, pertuzumab Lapatinib, sapitinib
IGF-1R IGF-1   Linsitinib, GSK1904529A
FGFR FGF   Nintedanib, NVP-BGJ398
FLT3 FLT3 ligand   Quizartinib, dovitinib
c-Kit Stem cell factor   Dovitinib, pazopanib
Tie-2 Angiopoietin   Pexmetinib
c-RET GDNF, neurturin, artemin, persephin   Regorafenib
TAM receptor Gas6, protein S   Sitravatinib
CSF-1R CSF-1   Linifanib
Ephrin receptor Ephrins   Sitravatinib
Trk receptor BDNF, NGF   Sitravatinib, larotrectinib
ACK    XMD8-87 [20]
Src    Bosutinib
ALK    Crizotinib